Edwards Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman
This article was originally published in The Gray Sheet
Executive Summary
Early clinical data profiling Edwards/Sangamo's EW-A-401 gene therapy for intermittent claudication (leg pain) in patients at the National Institutes of Health are expected to appear in the Oct. 19 issue of Circulation
You may also be interested in...
Edwards Studies Gene Therapy Compound As Vessel For Peripheral Growth
Edwards Lifesciences' legacy as a Baxter spin-off is allowing the cardiovascular firm to pursue clinical applications of a peripheral artery disease (PAD) gene therapy compound without integrating it with a device
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.